Skip to main content

Advertisement

Table 4 Adverse events possibly related to HDM/SCT (Grade >2)

From: Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial

Toxicity BD + HDM/SCT (n = 28) HDM/SCT (n = 28) Pvalue
Nausea or vomiting 8 (28.6%) 10 (35.7%) 0.78
Diarrhea 6 (21.4%) 7 (25%) 1.0
Mucositis 5 (17.9%) 7 (25%) 0.75
Hepatic 5 (17.9%) 5 (17.9%) 1.0
Renal 4 (14.3%) 6 (21.4%) 0.73
Cardiac 3 (10.7%) 6 (21.4%) 0.47
Febrile neutropenia 9 (32.1%) 7 (25%) 0.77
Sepsis 0 2 (7.1%) 0.5
  1. BD, bortezomib in combination with dexamethasone; HDM/SCT, high dose melphalan and autologous stem cell transplantation.